<HashMap><database>GEO</database><file_versions><headers><Content-Type>application/xml</Content-Type></headers><body><files><Other>ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE328nnn/GSE328835/</Other></files><type>primary</type></body><statusCodeValue>200</statusCodeValue><statusCode>OK</statusCode></file_versions><scores/><additional><omics_type>Other</omics_type><species>Homo sapiens</species><gds_type>Other</gds_type><full_dataset_link>https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE328835</full_dataset_link><repository>GEO</repository><entry_type>GSE</entry_type></additional><is_claimable>false</is_claimable><name>Identification of a G-quadruplex-forming cell-free DNA fragment as a biomarker for the precise diagnosis of hepatocellular carcinoma[cfDNA]</name><description>Early detection of hepatocellular carcinoma (HCC) remains challenging, as the currently recommended surveillance strategy based on ultrasound combined with alpha-fetoprotein (AFP) is limited by suboptimal sensitivity and accessibility. Cell-free DNA (cfDNA) provides a minimally invasive avenue for cancer detection. However, most existing cfDNA-based approaches either perform unreliably in low-input samples or require analytically complex workflows. Here, we systematically profiled serum cfDNA from individuals with HCC and without HCC and identified a high-abundance tumor-associated single cfDNA fragment at the FAM230F genomic region. Integrative analysis of liver assay for transposase-accessible chromatin with sequencing (ATAC-seq) revealed consistent tumor-specific chromatin accessibility at this locus, suggesting a tumor-derived origin. Structural characterization further demonstrated enrichment of G-quadruplex (G4) features within the target sequence, which may increase resistance to serum nuclease degradation and promote its preferential retention in circulation. Based on these properties, we established a qPCR-based detection workflow with clinical accessibility. In a validation cohort independent of the discovery cohort, a ΔCt cutoff of 2 was selected by maximizing the Youden index within the same cohort. The assay showed a sensitivity of 94.5% and a specificity of 90.5% for distinguishing HCC from non-HCC. Collectively, our study identifies FAM230F as a structurally stable tumor-associated cfDNA fragment and establishes a simple and scalable qPCR-based assay for HCC detection, providing a practical framework for translating cfDNA fragment analysis into clinical biomarkers.</description><dates><publication>2026/09/09</publication></dates><accession>GSE328835</accession><cross_references><GSM>GSM9690536</GSM><GSM>GSM9690535</GSM><GSM>GSM9690534</GSM><GSM>GSM9690533</GSM><GSM>GSM9690539</GSM><GSM>GSM9690538</GSM><GSM>GSM9690537</GSM><GSM>GSM9690543</GSM><GSM>GSM9690542</GSM><GSM>GSM9690541</GSM><GSM>GSM9690540</GSM><GSM>GSM9690525</GSM><GSM>GSM9690524</GSM><GSM>GSM9690523</GSM><GSM>GSM9690522</GSM><GSM>GSM9690529</GSM><GSM>GSM9690528</GSM><GSM>GSM9690527</GSM><GSM>GSM9690526</GSM><GSM>GSM9690532</GSM><GSM>GSM9690531</GSM><GSM>GSM9690530</GSM><GSM>GSM9690519</GSM><GSM>GSM9690514</GSM><GSM>GSM9690513</GSM><GSM>GSM9690512</GSM><GSM>GSM9690555</GSM><GSM>GSM9690511</GSM><GSM>GSM9690518</GSM><GSM>GSM9690517</GSM><GSM>GSM9690516</GSM><GSM>GSM9690515</GSM><GSM>GSM9690521</GSM><GSM>GSM9690520</GSM><GSM>GSM9690509</GSM><GSM>GSM9690508</GSM><GSM>GSM9690547</GSM><GSM>GSM9690503</GSM><GSM>GSM9690502</GSM><GSM>GSM9690546</GSM><GSM>GSM9690501</GSM><GSM>GSM9690545</GSM><GSM>GSM9690544</GSM><GSM>GSM9690500</GSM><GSM>GSM9690507</GSM><GSM>GSM9690506</GSM><GSM>GSM9690505</GSM><GSM>GSM9690549</GSM><GSM>GSM9690504</GSM><GSM>GSM9690548</GSM><GSM>GSM9690550</GSM><GSM>GSM9690510</GSM><GSM>GSM9690554</GSM><GSM>GSM9690553</GSM><GSM>GSM9690552</GSM><GSM>GSM9690551</GSM><GPL>24676</GPL><GSE>328835</GSE><taxon>Homo sapiens</taxon></cross_references></HashMap>